Prognozy (mln) dla Hanall Biopharma Co.,Ltd
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
141,600.00 |
151,216.67 |
173,525.00 |
194,100.00 |
275,000.00 |
295,000.00 |
| Przychód Δ r/r |
0.00% |
6.79% |
14.75% |
11.86% |
41.68% |
7.27% |
| Przychód (min) |
137,108.63 |
143,344.78 |
156,231.38 |
179,066.79 |
253,701.01 |
272,151.99 |
| Przychód (max) |
151,271.50 |
171,899.13 |
217,765.45 |
232,884.05 |
329,949.06 |
353,945.36 |
| EBITDA (średnia) |
9,214.28 |
9,840.07 |
11,291.73 |
12,630.60 |
17,894.97 |
19,196.43 |
| EBIT (średnia) |
5,426.06 |
5,794.56 |
6,649.41 |
7,437.84 |
10,537.89 |
11,304.28 |
| EBIT % |
3.83% |
3.83% |
3.83% |
3.83% |
3.83% |
3.83% |
| Zysk netto (średni) |
6,829.42 |
5,823.60 |
16,748.14 |
35,753.04 |
0.00 |
0.00 |
| Zysk netto % |
4.82% |
3.85% |
9.65% |
18.42% |
0.00% |
0.00% |
| EPS (średnia) |
134.67 |
114.83 |
330.25 |
705.00 |
0.00 |
0.00 |
| Liczba analityków (Przychody) |
7 |
7 |
7 |
3 |
4 |
3 |
| Liczba analityków (EPS) |
7 |
7 |
7 |
2 |
5 |
2 |
| symbol |
009420.KS |
009420.KS |
009420.KS |
009420.KS |
009420.KS |
009420.KS |